{'fraction_non_alphanumeric': 0.024260803639120546, 'fraction_numerical': 0.01061410159211524, 'mean_word_length': 6.674418604651163, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Inhibition of human neutrophil migration by supernatants from Hodgkin's disease‐derived cell lines

Abstract. The contribution of defective neutrophil function to the increased susceptibility to infection observed in patients with Hodgkin's disease is unclear. We describe cell‐directed inhibition of normal human neutrophil migration by serum‐free culture supernatants of the Hodgkin‐derived cell line L428 KSA, tentatively termed Hodgkin‐derived leucocyte factor (HDLF). This factor inhibits both random migration and migration toward different chemoattractants, appears to bind to the cell surface and is stable at 56°C but destroyed at 100°C. Hodgkin‐derived leucocyte factor also stimulates basal neutrophil superoxide production but the cells remain fully responsive to n‐formyl‐methionylleucylphenylalanine. Get filtration chromatography shows a single peak of migration‐inhibitory and superoxide‐stimulatory activity at approximately 70000 g mol‐1, Hodgkin‐derived leucocyte factor migration inhibition persists in neutro‐phils from a patient with chronic granulomatous disease. Activity of HDLF is completely destroyed by trypsin but unaffected by the protease inhibitor phenyl‐methylsulphonylfluoride. Hodgkin's factor appears to be different from previously described neutrophil migration inhibitory factors.